Rheumatoid ArthritisRISENCT02230943
Rheumatology Informatics System for Effectiveness
An observational study of Rheumatoid Arthritis and Osteoarthritis, run by American College of Rheumatology at 1 site in United States.
Trial summary
The RISE Registry is an enhanced version of the ACR's Rheumatology Clinical Registry (RCR) and allows for a simplified entry process, while establishing a best-in-class resource to manage your patient population and improve patient care. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Rheumatoid Arthritis, Osteoarthritis, Gout
- How many people
- 100,000 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2014to Dec 2015
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Primary care clinic
Who may be able to join
- Patients 18 years of age and older with one of the following diagnoses: rheumatoid arthritis, osteoarthritis, gout
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
American College of Rheumatology
Atlanta, Georgia, 30319
Melissa D. Francisco, 404-633-3777 ext. 102, mfrancisco@rheumatology.org
About this study
Official title: American College of Rheumatology's Rheumatology Informatics System for Effectiveness
The RISE Registry is an enhanced version of the ACR's Rheumatology Clinical Registry (RCR) and allows for a simplified entry process, while establishing a best-in-class resource to manage your patient population and improve patient care.
RISE provides participants with an infrastructure for robust quality improvement activities leading to improved patient outcomes, patient population management and quality reporting related to rheumatic diseases and drug safety. RISE gives physicians and researchers the information they need to optimize patient outcomes, meet reporting requirements, and make discoveries that advance rheumatology.
Read the detailed description
RISE helps providers benchmark performances on key rheumatology clinical quality measures and align with best practice standards. The RISE benchmarking tool allows providers to view the details of their patient population against established rheumatology quality metrics. RISE allows access to aggregate data from other participating sites so providers can view their patient population in comparison to other RISE participants.
RISE is integrated into an electronic health records (EHR) system, bringing a single point of entry into one solution for filing for quality-based incentive payments, avoiding penalties, complying with reporting requirements and tracking caseloads for quality monitoring and improvement initiatives. RISE collects the data needed to meet current federal reporting requirements.
Participating in RISE helps push the field of rheumatology practice forward. RISE provides a source of information on patient outcomes and quality care for rheumatology leading to new discoveries, better understanding and a source of comparative effectiveness research.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Gout
- Keywords
- rheumatoid, arthritis, osteoarthritis, gout
- Medical subject headings
- Arthritis, Rheumatoid, Osteoarthritis, Gout, Arthritis
What is being measured
The primary outcome is the main question the study is designed to answer.
Controlling High Blood Pressure
Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period.
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Sep 2014 (estimated)
- Study startApr 2014
- Primary completionDec 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100,000 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- American College of Rheumatology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02230943
- Sponsor's protocol ID
- RISE
- Acronym
- RISE
- Status last verified
- Aug 2014
- First submitted
- 29 Aug 2014
- Last updated
- 3 Sep 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- American College of Rheumatology's Rheumatology Informatics System for Effectiveness
- ClinicalTrials.gov ID
- NCT02230943
- Acronym / sponsor ID
- RISE / RISE
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Gout
- Keywords
- rheumatoid, arthritis, osteoarthritis, gout
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100,000 participants (estimated)
- Lead sponsor
- American College of RheumatologyUniversity, hospital or other
- Study start
- Apr 2014
- Primary completion
- Dec 2015 (estimated)
- First posted
- 3 Sep 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The RISE Registry is an enhanced version of the ACR's Rheumatology Clinical Registry (RCR) and allows for a simplified entry process, while establishing a best-in-class resource to manage your patient population and improve patient care.
RISE provides participants with an infrastructure for robust quality improvement activities leading to improved patient outcomes, patient population management and quality reporting related to rheumatic diseases and drug safety. RISE gives physicians and researchers the information they need to optimize patient outcomes, meet reporting requirements, and make discoveries that advance rheumatology.
Detailed description
RISE helps providers benchmark performances on key rheumatology clinical quality measures and align with best practice standards. The RISE benchmarking tool allows providers to view the details of their patient population against established rheumatology quality metrics. RISE allows access to aggregate data from other participating sites so providers can view their patient population in comparison to other RISE participants.
RISE is integrated into an electronic health records (EHR) system, bringing a single point of entry into one solution for filing for quality-based incentive payments, avoiding penalties, complying with reporting requirements and tracking caseloads for quality monitoring and improvement initiatives. RISE collects the data needed to meet current federal reporting requirements.
Participating in RISE helps push the field of rheumatology practice forward. RISE provides a source of information on patient outcomes and quality care for rheumatology leading to new discoveries, better understanding and a source of comparative effectiveness research.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Primary care clinic
Key inclusion criteria (1 listed)
- Patients 18 years of age and older with one of the following diagnoses: rheumatoid arthritis, osteoarthritis, gout
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Controlling High Blood Pressure
Time frame: one year
Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2014.
Related trials for Rheumatoid Arthritis
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
RecruitingPhase 2
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
Sjögren's Disease
Not yet recruitingPhase 1/2
Efficacy and Safety of Dapagliflozin as an Adjunct to Conventional Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis (RA
Active, not recruitingObservational study
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Rheumatoid Arthritis and Osteoarthritis, run by American College of Rheumatology at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Sep 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Melissa D Francisco (404-633-3777 ext. 102, mfrancisco@rheumatology.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Controlling High Blood Pressure (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2014.